Abstract:Background— Cardiotoxicity is a leading cause for drug attrition during pharmaceutical development and has resulted in numerous preventable patient deaths. Incidents of adverse cardiac drug reactions are more common in patients with preexisting heart disease than the general population. Here we generated a library of human induced pluripotent stem cell–derived cardiomyocytes (hiPSC-CMs) from patients with various hereditary cardiac disorders to model differences in cardiac drug toxicity susceptibility for patients of different genetic backgrounds. Methods and Results— Action potential duration and drug-induced arrhythmia were measured at the single cell level in hiPSC-CMs derived from healthy subjects and patients with hereditary long QT syndrome, familial hypertrophic cardiomyopathy, and familial dilated cardiomyopathy. Disease phenotypes were verified in long QT syndrome, hypertrophic cardiomyopathy, and dilated cardiomyopathy hiPSC-CMs by immunostaining and single cell patch clamp. Human embryonic stem cell–derived cardiomyocytes (hESC-CMs) and the human ether-a-go-go –related gene expressing human embryonic kidney cells were used as controls. Single cell PCR confirmed expression of all cardiac ion channels in patient-specific hiPSC-CMs as well as hESC-CMs, but not in human embryonic kidney cells. Disease-specific hiPSC-CMs demonstrated increased susceptibility to known cardiotoxic drugs as measured by action potential duration and quantification of drug-induced arrhythmias such as early afterdepolarizations and delayed afterdepolarizations. Conclusions— We have recapitulated drug-induced cardiotoxicity profiles for healthy subjects, long QT syndrome, hypertrophic cardiomyopathy, and dilated cardiomyopathy patients at the single cell level for the first time. Our data indicate that healthy and diseased individuals exhibit different susceptibilities to cardiotoxic drugs and that use of disease-specific hiPSC-CMs may predict adverse drug responses more accurately than the standard human ether-a-go-go –related gene test or healthy control hiPSC-CM/hESC-CM screening assays.

Dystrophin-deficient cardiomyocytes derived from human urine: new biologic reagents for drug discovery

Induced pluripotent stem cells from urine of Duchenne muscular dystrophy patients

Generation of Five Induced Pluripotent Stem Cell Lines with DMD/c.497G > T Mutation from Renal Epithelial Cells of a Duchenne Muscular Dystrophy Patient and a Recessive Carrier Parent

Drug Screening Using a Library of Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes Reveals Disease-Specific Patterns of Cardiotoxicity

Engineering Human Ventricular Heart Muscles Based on a Highly Efficient System for Purification of Human Pluripotent Stem Cell-Derived Ventricular Cardiomyocytes

Human-Induced Pluripotent Stem Cell-Based Differentiation of Cardiomyocyte Subtypes for Drug Discovery and Cell Therapy

Generation of a Urine-Derived Ips Cell Line from a Patient with a Ventricular Septal Defect and Heart Failure and the Robust Differentiation of These Cells to Cardiomyocytes via Small Molecules.

Generation of Induced Pluripotent Stem Cells from Urine

SNTA1 Gene Rescues Ion Channel Function in Cardiomyocytes Derived from Induced Pluripotent Stem Cells Reprogrammed from Muscular Dystrophy Patients with Arrhythmias

Small-molecule-based Generation of Functional Cardiomyocytes from Human Umbilical Cord-Derived Induced Pluripotent Stem Cells.

Skeletal myogenic differentiation of human urine-derived cells as a potential source for skeletal muscle regeneration.

Generation of induced pluripotent stem cell line (RCMGi009-A) from urine cells of patient with fibrodysplasia ossificans progressiva

Full-Length Dystrophin Restoration Via Targeted Exon Addition in DMD-Patient Specific Ipscs and Cardiomyocytes

Recombinant annexin A6 promotes membrane repair in a stem cell derived-cardiomyocyte model of dystrophic cardiomyopathy

CRISPR/Cas9-Based Dystrophin Restoration Reveals a Novel Role for Dystrophin in Bioenergetics and Stress Resistance of Muscle Progenitors

Urine-Derived Stem Cells: Biological Characterization And Potential Clinical Applications

Exosome-Derived Dystrophin from Allograft Myogenic Progenitors Improves Cardiac Function in Duchenne Muscular Dystrophic Mice

Urine-Derived Stem Cells: Differentiation Potential into Smooth-Muscle Cells and Urothelial Cell

Generation and Expansion of Human Cardiomyocytes from Patient Peripheral Blood Mononuclear Cells

Using low-risk factors to generate non-integrated human induced pluripotent stem cells from urine-derived cells

Generation of mesenchymal stromal cells from urine-derived iPSCs of pediatric brain tumor patients